Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.
East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor.
The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.
Related Articles

Huajin Securities: The spring market in January next year may continue, and technology is leading in some cyclical industries such as CKH HOLDINGS.

New stock prospects | 90% of revenue comes from the United States, how long can Universal Horticulture continue to benefit from going global?

ZheshangWhat is the impact of the equity market's year-end trend on the bond market?
Huajin Securities: The spring market in January next year may continue, and technology is leading in some cyclical industries such as CKH HOLDINGS.

New stock prospects | 90% of revenue comes from the United States, how long can Universal Horticulture continue to benefit from going global?

ZheshangWhat is the impact of the equity market's year-end trend on the bond market?

RECOMMEND

Not Just “Power Shortages,” Delays Will Become The Key Theme For U.S. Data Centers In 2026
26/12/2025

Hang Seng Index Rises 33% This Year, Best Five‑Year Performance; Multiple Institutions Forecast Breakthrough Above 30,000 Next Year
26/12/2025

Gold Rally Has Further To Run, JPMorgan Bullish: Prices Could Reach USD 5,055 By Year‑End 2026
26/12/2025


